Stabilization of NADH dehydrogenase in mitochondria by adenosine phosphates
Tóm tắt
It is known that one of the reasons leading to the development of neuroligical disorders, such as Parkinson’s disease, is the damage of the mitochondrial NADH dehydrogenase. We suggest that it happens when NADH dehydrogenase loses connection with its coenzyme flavine mononucleotide (FMN) in the active center. This process is blocked by the enzyme substrate NADH or by the reaction product NAD. In this work we have developed a method based on fluorescence spectroscopy to monitor the stability of FMN in isolated rat liver mitochondria. It was observed that this process is strongly blocked by adenine analogs ATP, ADP, and AMP. Adenine, adenosine, NADPH, nicotine amide, and nicotine acid did not prevent the FMN loss. The obtained data could be used as a basis for construction of synthetic analogues of adenosine phosphates for the treatment of mitochondrial diseases.
Tài liệu tham khảo
Seo B.B., Nakamaru-Ogiso E., Cruz P., Flotte T.R., Yagi T., Matsuno-Yagi A. 2004. Functional expression of the single subunit NADH dehydrogenase in mitochondria in vivo: A potential therapy for complex I deficiencies. Hum. Gene Ther. 15(9), 887–895.
Varghese M., Pandey M., Samanta A., Gangopadhyay P.K., Mohanakumar K.P. 2009. Reduced NADH coenzyme Q dehydrogenase activity in platelets of Parkinson’s disease, but not Parkinson plus patients, from an Indian population. J. Neurol. Sci. 279(1–2), 39–42.
Sokolova I.B., Vekshin N.L. 2008. Loss of flavine from NADH dehydrogenase mitochondrial complex. Biofizika (Rus.). 53(1), 73–77.
Vekshin N.L. 2009. Fluorestsentnaya spektroskopia biopolimerov (Fluorescence spectroscopy of biopolymers). Pushchino: Foton vek.
Belyakovich A.G. 1990. Izuchenie mitokhondrii i bakterii s pomoshchyu sol tetrazolia p-NTF (The study of bacteria and mitochondria by means of tetrazolium salts of p-NTF). Pushchino: ONTI NTsBI.
Sharova I.V., Vekshin N.L. 2004. Rotenone-insensitive NADH oxidation in the mitochondrial suspension is carried out by NADH dehydrogenase fragment of the respiratory chain. Biofizika (Rus.). 49(5), 814–821.
Vekshin N.L. 1988. Spectrophotometric determination of protein in biological standard suspensions. Biol. Sciences. 4, 107–111.
Zinina A.N., Vekshin N.L. 2008. Fluorimetric comparison of proto-mitohondria and mitochondria. Biol. Membrany (Rus.). 25(6), 480–487.
Vekshin N.L. 2010. Photometric and fluorimetric studies of proto-mitohondria from liver of old and young rats. Biol. Membrany (Rus.). 27(5), 424–429.
Galante Y.M., Hatefi Y. 1979. Purification and molecular and enzymic properties of mitochondrial NADH dehydrogenase. Arch. Biochem. Biophys. 192, 559–568.
Dooijewaard G., Slater E.C., Van Dijk P.J., De Bruin G.J. 1978. Chaotropic resolution of high molecular weight (type I) NADH dehydrogenase, and reassociation of flavin-rich (type II) and flavin-poor subunits. Biochim. Biophys. Acta. 503, 405–424.
Almeida T., Durante M., Melo A.M.P., Videira A. 1999. The 24-kDa iron-sulphur subunit of complex I is required for enzyme activity. Eur. J. Biochem. 265, 86–92.
Cremona T., Kerney E.B. 1964. Studies on the respiratory chain-linked reduced nicotinamide adenine dinucleotide dehydrogenase. J. Biol. Chem. 230(7), 328–333.
Okun J.G., Zickermann V., Zwicker K., Schagger H., Brandt U. 2000. Binding of detergents and inhibitors to bovine complex I—a novel purification procedure for bovine complex I retaining full ingibitor sensitivity. Biochim. Biophys. Acta. 1459, 77–87.
Grivennikova V.G., Vinogradov A.D. 2003. Mitochondrial complex I. Uspekhi Biol. Khimii (Rus.). 43, 19–58.
Vinogradov A.D. 1998. Catalytic properties of the mitochondrial NADH-ubiquinone oxidoreductase (complex I) and pseudo-reversible active/inactive enzyme transition. Biochim. Biophys. Acta. 1364, 169–185.
Grivennikova V.G., Vinogradov A.D. 2006. Generation of superoxide by mitochondrial complex I. Biochim. Biophys. Acta. 1757, 553–561.
Albracht S.P.J., Mariette A., De Jong P. 1997. Bovine-heart NADH: ubiquinone oxidoreductase is a monomer with 8 Fe-S clusters and 2 FMN groups. Biochim. Biophys. Acta. 1318, 92–106.
Bubnova T.V. 2009. Razreshennye lekarstvennye sredstva i BAD (Permitted drugs and BAAs). Penza: Belinsky University of Penza.